Frazier Lifesciences Acquisition Corporation
Equities
NAMS
NL00150012L7
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
18.6 EUR | -8.37% |
|
+2.78% | +81.74% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+81.74% | 1.8B | |
+15.58% | 121B | |
+16.60% | 110B | |
+18.78% | 25.93B | |
-24.33% | 19.27B | |
-19.54% | 16.01B | |
-17.95% | 15.66B | |
-46.81% | 14.89B | |
+58.78% | 14.47B | |
+4.91% | 13.91B |
- Stock Market
- Equities
- NAMS Stock
- News Frazier Lifesciences Acquisition Corporation
- NewAmsterdam Pharma Names David Topper CFO